Aronne 2025 — SURMOUNT-5 (Tirzepatide vs Semaglutide)

New England Journal of Medicine·April 4, 2025

Aronne LJ, Horn DB, le Roux CW, et al.

Summary

First direct head-to-head comparison. Tirzepatide achieved greater weight loss than semaglutide 2.4 mg in patients with obesity.

Study Details

Study Design

Phase 3b open-label, randomized head-to-head trial

Indication

Obesity/overweight

Intervention

Tirzepatide vs semaglutide 2.4 mg weekly

Species

Human

Sample Size

751 subjects

Risk of Bias Assessment

Open-label design; Lilly-sponsored